Harrow acquires U.S. commercial rights to BYQLOVI 0.05% from Formosa

Harrow (HROW) announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration, FDA, for the treatment of post-operative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15 years. Harrow expects BYQLOVI to be available in the fourth quarter of 2025. “We are thrilled to soon launch BYQLOVI, a truly clinically differentiated topical corticosteroid, into a U.S. market that now exceeds 7 million annual ophthalmic surgeries,” said Mark L. Baum, Chief Executive Officer of Harrow. “With compelling efficacy, extraordinary safety, and patient-friendly dosing, BYQLOVI has the potential to shift the paradigm in the multi-billion-dollar U.S. post-surgical care ophthalmic segment.”